<DOC>
	<DOC>NCT01986660</DOC>
	<brief_summary>The purpose of this study is to evaluate how Ibuprofen Cream (SST-0225) is absorbed and eliminated by the body under defined maximum dosing conditions and to evaluate the safety under these conditions.</brief_summary>
	<brief_title>Open-Label, Maximum-Dose Pharmacokinetic Study of 7.5% Ibuprofen Cream (SST-0225) in Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Ibuprofen</mesh_term>
	<criteria>Signed consent form Men, women, 18 to 55 years Females must not be pregnant or plan to become pregnant BMI 18 to 30 kg/m2 Past or nonsmoker High probability of compliance with completion of study Healthy as determined by investigator based on medical history, physical exam, clinical laboratory tests, vital sign measurements, ECGs Presence or history of disorder that could interfere with completion of study Unstable medical condition Surgical or medical condition that may interfere with absorption, distribution, metabolism or excretion of test drug Positive Hep B, Hep C and/or HIV test Positive urine drug screen Any history of skin disorders, including psoriasis, eczema, tattoos, significant scarring, healing wounds, skin lesions on knees or elbows Significant disease Any clinically important deviation from normal limits in physical exam, vital sign measurements, 12 lead ECG, clinical laboratory test History of drug abuse with 1 year History of alcoholism with 1 year Use of prescription medications or ibuprofen within 30 days of Day 1, use of OTC drugs, herbal supplements and vitamins within 14 days of Day 1. Use of investigational drug within 30 day of Day 1 Acute disease state within 7 days of Day 1 Consumption of grapefruit or grapefruit containing products within 72 hours of Day 1 Tobacco use/caffeine use within 48 hours of Day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Pharmacokinetic Study</keyword>
</DOC>